# ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis

- Source: PR Newswire General Business
- Published: 2026-10-30T11:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-approved-in-the-us-for-the-treatment-of-adults-with-active-psoriatic-arthritis-302924320.html
- Canonical: https://groundlevelnews.com/story/ilumya-tildrakizumab-asmn-approved-in-the-u-s-for-the-treatment-of-adu-e92b50/

IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis strengthening Sun Pharma's portfolio in psoriatic disease MUMBAI, India and PRINCETON, N.J., Oct. 30, 2026 /PRNewswire/ -- Sun...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire General Business._